BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 86.3%

Neg 0% Neu 86.3% Pos 0%

BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $8 price target.

Comments

No comments yet. Be the first!